Inscripta® Appoints Sri Kosaraju as President and CEO
Experienced growth-company leader joins as Inscripta embarks on next phase of commercial launch for its Onyx™ digital genome engineering platform
Read More
Inscripta® Raises $125M in Series D Financing to Accelerate Commercialization of Revolutionary Digital Genome Engineering Platform
New Funding Brings Total Amount Raised by the Company to $259.5 Million
Read More
Inscripta® Launches the World’s First Benchtop Platform for Digital Genome Engineering
The Onyx® platform enables scientists to create libraries of millions of precisely engineered single cells in one experiment through a...
Read More
Inscripta® Is the Presenting Sponsor of SynBioBeta 2019
Company is launching the world’s first benchtop platform for scalable Digital Genome Engineering at the conference
Read More
Inscripta® Appoints Jim Lalonde to Lead Microbial Digital Genome Engineering Business and Portfolio Strategy
Inscripta today named Jim Lalonde, Ph.D. to its management team
Read More
Inscripta® Expands Management Team with Appointment of Three Senior Bioinformatics and Computational Biology Experts
World’s first benchtop platform for scalable digital genome engineering to be launched at SynBioBeta conference in October
Read More
Inscripta® to present first data from its digital genome engineering technology at upcoming synthetic biology conference
Results from a 200,000-edit library of an E. coli biosynthesis pathway show unprecedented scale and variety of edit types
Read More
Inscripta® Appoints Ron McGrath as Chief Financial Officer
Inscripta, developer of the first scalable platform for benchtop digital genome engineering, today announced the appointment of Ron McGrath as...
Read More
Inscripta® Completes $20M Expansion of Series C Financing, Increasing Total Round to $105.5M
Continued support of existing investors will fund commercialization efforts, product launch later this year
Read More
In the First Year of Release, Inscripta®’s MAD7™ CRISPR Enzyme is Widely Adopted by the Gene-Editing Community
Existing investors contribute an additional $30 million to accelerate tools that will revolutionize genomic research
Read More